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Abstract
Background: Fine scale geospatial analysis of HIV infection patterns can be used to facilitate geographically
targeted interventions. Our objective was to use the geospatial technology to map age and time standardized HIV
incidence rates over a period of 10 years to identify communities at high risk of HIV in the greater Durban area.
Methods: HIV incidence rates from 7557 South African women enrolled in five community-based HIV prevention
trials (2002–2012) were mapped using participant household global positioning system (GPS) coordinates. Age and
period standardized HIV incidence rates were calculated for 43 recruitment clusters across greater Durban. Bayesian
conditional autoregressive areal spatial regression (CAR) was used to identify significant patterns and clustering of
new HIV infections in recruitment communities.
Results: The total person-time in the cohort was 9093.93 years and 613 seroconversions were observed. The overall
crude HIV incidence rate across all communities was 6·74 per 100PY (95% CI: 6·22–7·30). 95% of the clusters had HIV
incidence rates greater than 3 per 100PY. The CAR analysis identified six communities with significantly high HIV
incidence. Estimated relative risks for these clusters ranged from 1.34 to 1.70. Consistent with these results, age
standardized HIV incidence rates were also highest in these clusters and estimated to be 10 or more per 100 PY.
Compared to women 35+ years old younger women were more likely to reside in the highest incidence areas
(aOR: 1·51, 95% CI: 1·06–2·15; aOR: 1.59, 95% CI: 1·19–2·14 and aOR: 1·62, 95% CI: 1·2–2·18 for < 20, 20–24, 25–29
years old respectively). Partnership factors (2+ sex partners and being unmarried/not cohabiting) were also more
common in the highest incidence clusters (aOR 1.48, 95% CI: 1.25–1.75 and aOR 1.54, 95% CI: 1.28–1.84
respectively).
Conclusion: Fine geospatial analysis showed a continuous, unrelenting, hyper HIV epidemic in most of the greater
Durban region with six communities characterised by particularly high levels of HIV incidence. The results motivate
for comprehensive community-based HIV prevention approaches including expanded access to PrEP. In addition, a
higher concentration of HIV related services is required in the highest risk communities to effectively reach the
most vulnerable populations.
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Background
South Africa has over 7 million human immunodeficiency
virus (HIV) infected individuals [1, 2]. HIV prevalence in
the country varies greatly across the provinces [3] and is
highest in KwaZulu-Natal (KZN). The reasons for the
higher burden in KZN (particularly among young women
and girls) are multi-faceted and dependent on complex
economic and localised social, behavioural and cultural
factors [4]. Coupled with high HIV infection rates, is the
high prevalence and incidence of other curable sexually
transmitted infections (STIs) [5]. Furthermore, factors
such as age of sexual debut [6], having a male partner aged
25–34 [7, 8], being unmarried or not living with a partner
[9], multiple sexual partners [10, 11], lack of condom use
[1], living in a low antiretroviral therapy (ART) coverage
area [12] and high mobility [13], have also been reported
as contributing factors in a young woman’s vulnerability
to the risk of HIV acquisition.
Given the persistent high HIV incidence rates, particu-
larly among young women in KZN [14], it is clear that
more effective approaches are required to tackle the epi-
demic [15–20]. One aspect receiving increasing interest
is finer scale geo-spatial analysis of HIV infection pat-
terns to facilitate more appropriate and geographically
targeted interventions [21, 22]. Previous studies have fre-
quently demonstrated the profound impact of HIV clus-
tering on the spread of the disease [23–25].
Furthermore, given the current climate of declining
funds and consistent with the global recommendations
from the Joint United Nations program on HIV/AIDS
(UNAIDS), optimal allocation of the limited resources
requires identification of the geographical patterns and
clustering of new HIV infections [26]. The HIV Preven-
tion Research Unit (HPRU) of the South African Med-
ical Research Council (SAMRC) had participated in
several large-scale HIV prevention trials from 2002 to
2012. The trials have been conducted among several
community-based research sites located across the
greater Durban region. These trials primarily sought to
determine the efficacy of various female initiated HIV
prevention options; however, investigational products
being tested found no effect on preventing HIV infec-
tions [15–19]. The primary objective of this study is to
assess the geographical variations and clustering of HIV
infections at a localized level in recruitment communi-
ties. Results from our study will guide policy makers to
develop tailored prevention strategies in order to allocate
scarce resources by targeting the most at risk individuals
at a sub-geographical level.
Methods
Study area and population
From 2002 to 2012, the HPRU of the SAMRC participated
in five international multi-centre HIV prevention clinical
trials [15–19]. A total of 9145 consenting women were en-
rolled in this combined cohort over the period of ten
years. All consenting women’s places of residence (or
nearest location point to residence) were geo-coordinated
using Geographic Positioning System (GPS) at the time of
enrolment and updated during follow-up visits (Add-
itional file 2: Table S1 details the participating communi-
ties). We had access to GPS data of 7557 women, which
were included in this analysis (Fig. 1).
GPS coordinate data were collected using Garmin™
Nüvi (model 2360) handheld devices, downloaded into
Microsoft Access and plotted spatially using ArcGIS
(version 10·4, CA). A total of 43 community-level re-
cruitment area boundaries were developed based on cen-
sus delineations [27].
Recruitment of trial participants was from communi-
ties in urban (peri-urban) and rural areas. Details of the
study population have been described elsewhere [15–
18]. For the purpose of the present analysis, data for
women that were common across the clinical trials was
extracted, combined and reported as unidentified and
not study or site-specific [15–19, 28].
HIV incidence was the endpoint of all trials included
in this analysis. HIV diagnostic testing was conducted
using two rapid tests on whole blood sourced from ei-
ther finger-prick or venepuncture (Determine HIV-1/2,
Abbot Laboratories, Tokyo, Japan and Oraquick, Ora-
sure Technologies, Bethlehem, PA, USA). The Abbot
IMX Enzyme-linked immunosorbent assay (ELISA) test
(Abbot Diagnostics, Africa Division), in combination
with the Vironostika HIV1/2 ELISA was used on whole
blood sourced from venepuncture for discordant/un-
equivocal results.
The age eligibility criteria were consistent across all
trials (> 18 years of age) except for one which enrolled
women aged 16 and older. Median age across the trials
varied marginally between 24 and 28 years. The average
screening to enrolment ratio was 47% in this combined
cohort. Other eligibility criteria were broadly similar for
all studies. At each visit, participants received HIV risk
reduction counselling, STI testing and treatment and
had access to male and/or female condoms. Women
who tested HIV positive at screening were referred to
local health care facilities for care and support. Women
who HIV seroconverted during the trial remained in the
study and received ongoing safe sex counselling, STI
testing and treatment, and condom provision. All partic-
ipants provided written informed consent to participate
in the studies.
Socio-demographic data collection
Data pertaining to age, contraceptive use, STI at screen-
ing (Chlamydia, Gonorrhoea, Syphilis and Trichomonas)
and condom use at last sex act was consistent across all
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five clinical trials. Four of the clinical trials included
marital status/cohabiting and parity data collection. The
number of sex partners in the last three months was col-
lected in three of the five clinical trials.
Characterisation of high incidence communities
Participant data were classified into five age categories
(< 20, 20–24, 25–29, 30–34, 35+ years old) across
three-time ranges (2003–2006, 2007–2009 and 2010–
2012). HIV incidence rates were calculated in each of fif-
teen strata (5 age groups and 3 time periods) in every re-
cruitment area and a combined weighted estimate for
each recruitment area was calculated. We employed dir-
ect age-time period standardization to obtain standard-
ized HIV incidence estimates per area to facilitate
legitimate geographical comparison (free from the influ-
ence of underlying differences in the age-composition of
participants in different areas as well as overall incidence
changes over time). The reference population was all
women enrolled in the HIV prevention trials conducted
at HPRU sites between 2002 and 2012.
The characteristics of the study population were com-
pared across pre-defined HIV incidence rate categories
(≤5, 5–6·9, 7–8·9 and 9+ per 100 person-year (PY)) as
the dependent ordinal variable. This analysis utilised
data at the individual women-level within this ordinal
variable. Age, marriage/cohabitation, type of contracep-
tion used, STI at baseline, number of sexual partners in
the last three months and parity data were included as
the explanatory variables at the individual level. Univari-
able and multivariable ordered logistic regression, with
recruitment area (community or group of communities)
cluster robust standard errors, were used to identify
prominent factors associated with higher incidence.
Stepwise forward selection regression (inclusion if p <
0·10) was used to construct the final multivariable
model. Adjusted odds ratios (aOR) and 95% confidence
intervals (CI’s) are presented in Table 1. The propor-
tional odds (or parallel regression) assumption for this
modelling approach was checked and upheld (Brant’s
test) [29].
An aggregate of women’s residence per recruitment
area representing a minimum of 50 PY were included in
HIV incidence rate calculations (n = 7557) following ex-
clusion of a) outlying participants not resident within
core recruitment areas (n = 194), or residing in areas
with less than 50 total PY (n = 207), (b) participants for
whom no GPS data had been collected (n = 1054) and
(c) participants who did not attend any follow up visits
post enrolment (n = 133) (Fig. 1). The crude HIV inci-
dence rate across all communities was calculated by div-
iding the number of seroconversions by total
person-years of observation.
Micro-geographical clustering analysis
We employed the most widely used Bayesian conditional
autoregressive (CAR) hierarchical model to assess inci-
dence risk across the 43 areas and mapped the relative
risk for each community (Figure 3) [30]. Bayesian hier-
archical models are one of the main statistical ap-
proaches for making inferences regarding the underlying
relative risks of a given disease across often disjointed
geographical areas. In addition to the parameters to ac-
count for shared boundaries (neighbouring areas) and
Fig. 1 Flowchart for estimating age and time period standardized HIV Incidence rates
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unmeasured heterogeneity within areas, we also included
additional covariate terms for age and time period to ac-
count for the potential confounding effect of these co-
variates and how they may vary across the 43 suburbs.
We employed a Bayesian conditional autoregressive
(CAR) hierarchical model to assess incidence risk across
the 43 areas and mapped the relative risk for each com-
munity. Bayesian hierarchical models are most com-
monly used to address the problems posed by small area
analysis. We utilised the Besag, York and Molliè (BYM)
or convolution CAR model, which is formulated as
follows:
Table 1 Characteristics of the study population by the categories of the HIV incidence rates and multivariable regression analysis
Total N (%) ≤5 per 100PY 5–6.9 per 100PY 7–8.9 per 100PY 9+ per 100PY Adjusted OR p-value
Age group
< 20 768 (10%) 75 (7%) 321 (11%) 199 (10%) 173 (10%) 1.51 (1.06–2.15)* 0.023
20–24 2606 (34%) 346 (33%) 986 (35%) 667 (34%) 607 (35%) 1.59 (1.19–2.14)* 0.002
25–29 1602 (21%) 239 (23%) 576 (21%) 382 (20%) 405 (23%) 1.62 (1.2–2.18)* 0.001
30–34 1027 (14%) 166 (16%) 386 (14%) 240 (12%) 235 (13%) 1.33 (0.98–1.82) 0.069
35+ 1554 (21%) 231 (22%) 539 (19%) 443 (23%) 341 (19%) 1
Education
None 3322 (55%) 577 (56%) 1189 (52%) 637 (50%) 919 (60%) 1
Primary 2485 (41%) 436 (42%) 992 (44%) 535 (42%) 522 (35%) 0.8 (0.7–0.92)* 0.002
Secondary or higher 281 (5%) 19 (2%) 89 (4%) 92 (7%) 81 (5%) 1.46 (1.1–1.95)* 0.009
Contraceptive use at baseline
None 1079 (14%) 108 (10%) 416 (15%) 356 (18%) 199 (11%) 1
Male/Female condom 1095 (15%) 125 (12%) 386 (14%) 305 (16%) 279 (16%) 1.14 (0.65–2.01) 0.639
IUD or Sterile 619 (8%) 107 (10%) 222 (8%) 183 (10%) 107 (6%) 1.28 (0.71–2.29) 0.406
Oral contraceptives 784 (10%) 168 (16%) 250 (9%) 146 (8%) 220 (13%) 1.71 (1.02–2.86)* 0.041
Injectables 3980 (53%) 549 (52%) 1534 (55%) 941 (49%) 956 (54%) 1.81 (1.1–2.96)* 0.019
Condom use at last sex
Yes 4850 (66%) 704 (70%) 1859 (68%) 1079 (58%) 1208 (70%)
No 2491 (34%) 303 (30%) 877 (32%) 792 (42%) 519 (30%) 1.09 (0.998–1.19) 0.056
Any STI
No 6193 (82%) 900 (85%) 2293 (82%) 1569 (81%) 1431 (81%) –
Yes 1356 (18%) 156 (15%) 511 (18%) 361 (19%) 328 (19%) 1.04 (0.87–1.23) 0.664
Number of sex partners
1 3929 (86%) 547 (89%) 1491 (86%) 1108 (85%) 783 (84%) 1
2+ 661 (14%) 69 (11%) 238 (14%) 199 (15%) 155 (16%) 1.48 (1.25–1.75)* < 0.001
Parity
0 757 (13%) 79 (10%) 342 (13%) 170 (11%) 166 (14%) 1.23 (0.91–1.68) 0.18
1 2610 (43%) 340 (42%) 1075 (43%) 634 (43%) 561 (46%) 1.13 (0.87–1.46) 0.356
2 1348 (22%) 212 (26%) 528 (21%) 326 (22%) 282 (23%) 1.09 (0.85–1.39) 0.489
3+ 1317 (22%) 175 (22%) 575 (23%) 358 (24%) 209 (17%)
Married/Cohabiting
No 4467 (74%) 478 (59%) 1890 (75%) 1145 (77%) 954 (78%) 1.54 (1.28–1.84)* < 0.001
Yes 1564 (26%) 327 (41%) 629 (25%) 344 (23%) 264 (22%) 1
Note:
Age group, education, contraceptive use, number of sex partners and marital status were significant in mulivariable analysis. Adjusted odds ratios for condom use
a last sex, STI at screening and parity were computed by adjusting for the aforementioned significant variables
Multivariable ordered logistic regression model based on participants who had complete data for all variables. The likelihood ratio test indicated that there was no
violation of the proportional odds assumption in the final ordered logistic regression model that was fitted (p-value 0.100)
aOR Adjusted Odds Ratio
IUD Intrauterine device
STI Sexually-transmitted Infection
* Statistically significant (p-value < 0.05)
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OiPoisson Eiγ i
 
log γ i
  ¼ αþ εi þ φi
where γi is the standardised relative risk in area i = 1 to
43, Oi is the number of incident HIV events in area i, Ei
is the expected number of incidence events based on
person time contribution, εi is the small area unstruc-
tured random effect term (to capture unstructured het-
erogeneity) and φi is the CAR spatial term (to capture
structured variation). We used an adjacency matrix of
common neighbouring areas (shared boundaries) of a
given suburb when modelling this parameter whereby φi
is the sum of the weighted neighbourhood values; εi was
modelled assuming an independent normal distribution
εi  Nð0; σ2ε ) with variance σ2ε . Non-informative gamma
priors were used for variance parameters in both the un-
structured and structured random effects.
In addition to the classical parametrization of the
model proposed by BYM we also included additional co-
variate terms for age and period of the individual within
the regions 1 to 43 to account for the confounding effect
of these covariates and how they may vary across the 43
suburbs. Markov chain Monte Carlo simulation
(MCMC) was used to fit this model [30] and imple-
mented in the Bayesian software package WinBUGS
[31]. Visual inspection of the parameter series plots was
used to assess model convergence as well as by using
Gelman-Rubin statistics [32].
Ethics approval and consent to participate
Ethical approval for the trials were received from the
University of KwaZulu-Natal Biomedical Research Ethics
Committee and the South African Medical Research
Council ethics committee.
Results
The total person-time in the cohort was 9093.93 years
and 613 seroconversions were observed.
Characterisation of the participants
Demographic characteristics and baseline sexual behav-
iour of women are presented overall and across the cat-
egories of HIV incidence rates (Table 1). The mean and
standard deviation of age in the cohort was 27.75 and
7·86, respectively. More than 60% of the women partici-
pants were less than 30 years old. Majority of the women
(> 80%) were unmarried and/or not living with their sex-
ual partners and more than half of the women had no
education. The most commonly used contraception at
baseline were injectables (53%); while 10 and 15% of the
study population reported using oral contraceptives and
male/female condoms respectively. Approximately two
thirds of women reported condom-use during their last
sex act. At baseline, prevalence of STIs exceeded 18% in
the 5–6.9, 7–8·9 and 9+ incidence categories compared
with 15% in the ≤5 HIV incidence category. Most
women had already given birth previously; specifically,
43, 22 and 22% reported having 1, 2 and 3 children
respectively.
Compared to the women 35+ years old, younger
women were significantly more likely to be in the high-
est HIV incidence category (aOR 1.51, 95% CI: 1.06–
2.15; aOR 1.59, 95% CI: 1.19–2.14 and aOR 1.62, 95%
CI: 1.2–2.18for < 20, 20–24, 25–29 years old respect-
ively). Women who had two or more sex partners were
50% more likely to be in a higher HIV incidence area
compared to women with a single partner (aOR 1.48,
95% CI:1.25–1.75; p < 0.001). A similar finding was ob-
served for women who were unmarried or not cohabit-
ing (aOR 1.54, 95% CI: 1.28–1.84; p < 0.001).
Micro-geographical clustering analysis
Estimated relative risks (RRs) from the Bayesian CAR
model were estimated across the 43 sub-geographical
units and presented in Additional file 1: Figure S1. Our
analysis identified six clusters located centrally and in
the northern neighbouring areas of Durban (Figure 2).
Estimated RRs for these clusters ranged from 1.34 to
1.70. Consistent with these results, age standardized
HIV incidence rates were also highest in these clusters
and estimated to be as high as 10 to 11 per 100 PY.
Discussion
Through finer geospatial analysis of our data from over
7000 women participants, we observed a continuous and
unrelenting hyper HIV epidemic in the greater Durban
area over a ten-year period; with HIV incidence rates
ranging from 3 to 12 per 100 woman-year (WY). These
high HIV incidence rates were observed among trial par-
ticipants who received regular HIV pre- and post- test
counselling, safe sex counselling, treatment of curable
STIs and male and female condom promotion. The high
incidence rate observed during this period are similar to
that reported from the CAP004 trial [33]; conducted be-
tween 2007 and 2009 in Durban. In that trial HIV inci-
dence rates in the placebo group was reported to be 9/
100 PY. Similarly, a cohort study by Nel et al. (2007–
2009) observed an HIV incidence rate of 7.2/100 PY in
the greater Durban area [34]. More recent data from the
ASPIRE trial [35] showed that HIV incidence rates
ranged from 5.4/100py to 8/100PY in the same commu-
nities from which this combined data was generated.
The ASPIRE trial, suggested a slight decline in HIV inci-
dence in these communities, However, rates as high as
8/100PY are unacceptable given the aggressive roll out
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of ARV treatment and access to standard prevention op-
tions in the country [35].
This is the first comprehensive study to analyse the
geographic variation and clustering of HIV incidence
rates among women in the greater Durban region. This
study has several strengths which overcome many limi-
tations which usually arise with averaged incidence maps
(with often low number of events which make robust
statistical interference difficult). We employed a Bayes-
ian CAR model, which simultaneously estimates stable
spatial and temporal structured patterns and departures
from these stable components. In doing so we could
capture spatial correlations or unobserved heterogeneity
in HIV incidence that cannot be explained by time and
other covariates. Results from this analysis underscored
several pockets or clusters with high HIV infections in
the greater Durban region. These areas were confined to
central and northern territories. Previous work con-
ducted in KwaZulu-Natal has examined the
micro-geographical patterns of HIV prevalence [36] and
HIV incidence in a rural setting over a decade of demo-
graphic surveillance [35]. However, no comparative work
has been done in an urban setting in Northern
KwaZulu-Natal. Similarly, our findings presented prom-
inent heterogeneity in HIV rates in a relatively small
geographic extent. In totality, these studies suggest ap-
parent ‘corridors’ of elevated transmission [37] in the re-
gion which, based on the findings herein, may also be
Fig. 2 Relative risks (RRs) from the Bayesian conditional autoregressive (CAR) model and age-period adjusted HIV incidence rates (per 100 PY) for
the six clusters with significantly higher incidence rate
Ramjee et al. BMC Infectious Diseases          (2019) 19:500 Page 6 of 9
seen in other urban/peri-urban communities of KZN, as
well as other similar hyper-endemic rural populations.
Concurrent with the previous studies, our results also
provided additional evidence that these geographically
clustered areas could be further differentiated with
established risk factors for HIV seroconversion [6–12,
38–40]. As observed in our data, a large number of
women, especially younger women, do not seem to be in
a stable relationship and are likely to have multiple part-
ners, use barrier methods less frequently thus potentially
increasing their risk of HIV acquisition. This was further
confirmed by high rates of other curable STIs. These
findings are in keeping with those reported previously in
KwaZulu-Natal [41]. Research on the role of STIs and
inflammation and its impact on the vaginal microbiome
and HIV acquisition risk is currently gaining inter-
national interest [42–44]. While behavioural and struc-
tural risks are important drivers of the HIV acquisition
[45], considerable research is being undertaken to under-
stand biological risk of HIV acquisition. It is more likely
that in our region, all three risks play a significant role
in the risk of HIV acquisition. Consistent with the previ-
ous studies, we also showed that women who use inject-
able and oral contraceptives are at a greater risk of being
in a high HIV incidence category. These findings are
similar to what we observed in another study [46].
Our results and that of others [41] have consistently
shown that younger women are at a greater increased
risk of being in the higher HIV incidence categories
[47]. More recently, Akullian et al. [8] and de Oliviera et
al. [7] showed that when these young women form sex-
ual relationships with men aged 25–34 years of age, they
are at particularly high risk for acquiring HIV.
South Africa has the largest ART programme in the
world with just over 3.4 million individuals receiving
medication [48]. The implementation of universal
changes to national policies has been slow with sporadic
uptake of ART from HIV positive participants, especially
during the earlier period of the trials. This could explain,
at least in part, some of the intra-community HIV inci-
dence variability as well as the ubiquitously high rates of
infection throughout. In addition, these findings provide
further evidence for multiple sub-epidemics within a sin-
gle region [49] in line with findings from KwaZulu-Natal
[37] and other parts of Africa [50–52]. While under-
standing the spatial structure of HIV burden may allow
for an appropriate concentration of services at a
micro-geographic level, our data depicts an overall high
HIV incidence among women in the entire greater Dur-
ban area and calls for a more blanketed and
community-wide intervention and prevention efforts to
have a major impact in this setting, with a particular
focus on addressing the key drivers of the higher inci-
dence identified among this population. In addition to
this strategy, using the identified HIV clusters (that may
be acting as a node for onward transmission) provides
motivation for those communities to receive additional
benefit from a more structured and concentrated HIV
prevention and intervention approach. Targeting these
HIV clusters may have numerous benefits. Firstly, such
pockets of HIV are thought to re-seed nearby popula-
tions and may concurrently act as a potential “source of
attraction” for HIV positive individuals from other com-
munities. Secondly, targeting high risk areas is econom-
ically viable especially in resource constrained settings
and provides an ideal starting point for ART implemen-
tation and scale-up of treatment as prevention (TasP); a
strategy that is imperative to break onward HIV trans-
mission. Indeed, without TasP implemented in such HIV
concentrated pockets, one may observe a decreased effi-
cacy of existing population-based intervention pro-
grammes. Furthermore, it has been previously
demonstrated that ART adherence, and indeed uptake, is
heavily negatively impacted by geographical barriers. It
therefore makes placement of ARV clinics logistical, eco-
nomical and ethical sense to target vulnerable individ-
uals, aid adherence issues and ultimately achieve
maximum penetration of HIV-related services to
high-risk areas. This, in addition to a more blanketed
intervention and prevention effort, may be the most suc-
cessful strategy in reducing HIV incidence in a region
with a burgeoning HIV epidemic.
The fact that socio-demographic information was not
consistently collected across all trials, does pose a limita-
tion and highlights the issue of missing data. A key issue
in the extrapolation of data from clinical trials is the
generalisability of the incidence data to women in the
same geographical area. This may be a limitation of the
study where we report on women, mostly of
child-bearing age, that participated in a HIV prevention
clinical trial. These women may perceive their risk for
HIV as higher than the general population, due to indi-
vidual circumstances and experiences. However, we uti-
lised a consistent set of inclusion and exclusion criteria
to enrol women across the decade of clinical trials. This
consistency in eligibility (combined with the age and
period standardisation approach employed) means that
we are comparing a similar sample of women in all areas
across time and space. It is thus unlikely that such selec-
tion effects could account for the remarkable spatial het-
erogeneity observed.
Conclusion
Despite this unfortunate and rather unwelcome result,
moving forward there is a clear need to intensify HIV
treatment and prevention initiatives in a two-pronged
approach. Firstly, due to the unacceptably high HIV inci-
dence in all communities in Durban, an aggressive
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approach to combination prevention strategies including
highly effective pre-exposure prophylaxis (PrEP) is
needed. Although PrEP is registered for HIV prevention
in the country, the roll-out programs are focussed on
high risk groups such as men who have sex with men
(MSM), sex workers and students. We make a case for
universal roll out of PrEP in the greater Durban region
with focus on individual risk assessment and provision
and monitoring through innovative community-based
programs. Secondly, those communities which are clear
clustered transmission nodes, need a greater concentra-
tion of HIV related services (such as increased availabil-
ity of HIV/STI clinics, access to treatment), where
individuals at higher risk are targeted, and ultimately act
as a powerful adjunct to prevention efforts to have a
major impact in this setting.
Additional files
Additional file 1: Figure S1. Community level HIV incidence rates using
Bayesian conditional autoregressive (CAR) areal spatial regression analysis.
(DOCX 313 kb)
Additional file 2: Table S1. Description of studies included in cluster
analysis detection. (DOCX 14 kb)
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